| The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies A Daei Sorkhabi, L Mohamed Khosroshahi, A Sarkesh, A Mardi, ... Frontiers in immunology 14, 1113882, 2023 | 43 | 2023 |
| Biological causes of immunogenic cancer cell death (ICD) and anti-tumor therapy; combination of oncolytic virus-based immunotherapy and CAR T-cell therapy for ICD induction A Mardi, AV Shirokova, RN Mohammed, A Keshavarz, AO Zekiy, ... Cancer Cell International 22 (1), 168, 2022 | 42 | 2022 |
| Interleukin-1 in COVID-19 Infection: Immunopathogenesis and Possible Therapeutic Perspective A Mardi, S Meidaninikjeh, S Nikfarjam, N Majidi Zolbanin, R Jafari Viral immunology 34 (10), 679-688, 2021 | 41 | 2021 |
| Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies A Keshavarz, A Salehi, S Khosravi, Y Shariati, N Nasrabadi, MS Kahrizi, ... Stem Cell Research & Therapy 13 (1), 482, 2022 | 16 | 2022 |
| Molecular landscape of LncRNAs in bladder cancer: From drug resistance to novel LncRNA-based therapeutic strategies A Mehmandar-Oskuie, K Jahankhani, A Rostamlou, S Arabi, ZS Razavi, ... Biomedicine & Pharmacotherapy 165, 115242, 2023 | 8 | 2023 |
| Survivin; a novel therapeutic target that correlates with survival of autoreactive T lymphocytes obtained from patients with ankylosing spondylitis N Shomali, B Baradaran, AD Sorkhabi, A Sarkesh, MS Kahrizi, F Tosan, ... Gene 844, 146829, 2022 | 8 | 2022 |
| Restoration of miR-648 overcomes 5-FU-resistance through targeting ET-1 in gastric cancer cells in-vitro P Aliabadi, M Sadri, G Siri, F Ebrahimzadeh, Y Yazdani, AM Gusarov, ... Pathology-Research and Practice 239, 154139, 2022 | 8 | 2022 |
| The evaluation of CD39, CD73, and HIF-1 α expression besides their related miRNAs in PBMCs of women with recurrent pregnancy loss F Parhizkar, A Kiani, S Darzi, R Motavalli, FN Dolama, Y Yousefzadeh, ... Journal of Reproductive Immunology 156, 103820, 2023 | 6 | 2023 |
| Dysregulation of miR-193a serves as a potential contributor to MS pathogenesis via affecting RhoA and Rock1 N Saeidi, H Goudarzvand, H Mohammadi, A Mardi, S Ghoreishizadeh, ... Multiple Sclerosis and Related Disorders 69, 104468, 2023 | 6 | 2023 |
| Molecular mechanism of lncRNAs in pathogenesis and diagnosis of auto-immune diseases, with a special focus on lncRNA-based therapeutic approaches A Mehmandar-Oskuie, K Jahankhani, A Rostamlou, N Mardafkan, ... Life Sciences, 122322, 2023 | 4 | 2023 |
| Everolimus treatment enhances inhibitory immune checkpoint molecules’ expression in monocyte-derived dendritic cells B Naseri, A Mardi, A Khosrojerdi, E Baghbani, L Aghebati-Maleki, ... Human Immunology 85 (3), 110798, 2024 | 1 | 2024 |
| Nanocurcumin modulates Th17 cell responses in moderate and severe COPD patients A Mardi, S Abdolmohammadi-Vahid, SA Sadeghi, S Jafarzadeh, ... Heliyon 10 (9), 2024 | | 2024 |
| Unmasking the NLRP3 inflammasome in dendritic cells as a potential therapeutic target for autoimmunity, cancer, and infectious conditions S Alipour, A Mardi, N Shajari, T Kazemi, MR Sadeghi, JA Heris, ... Life Sciences, 122686, 2024 | | 2024 |
| Current approaches in glioblastoma multiforme immunotherapy M Aghajani, N Jalilzadeh, A Aghebati-Maleki, A Yari, P Tabnak, A Mardi, ... Clinical and Translational Oncology, 1-29, 2024 | | 2024 |
| Decoding contextual crosstalk: revealing distinct interactions between non-coding RNAs and unfolded protein response in breast cancer N Karamali, A Daraei, A Rostamlou, R Mahdavi, Z Akbari Jonoush, ... Cancer Cell International 24 (1), 104, 2024 | | 2024 |
| Casting Light on the Janus-Faced HMG-CoA Reductase Degradation Protein 1: A Comprehensive Review of Its Dualistic Impact on Apoptosis in Various Diseases RK Moghadam, A Daraei, M Haddadi, A Mardi, N Karamali, ... Molecular Neurobiology, 1-22, 2024 | | 2024 |
behzad baradaranImmunology Research Center, Tabriz University of Medical Sciences在 tbzmed.ac.ir 的电子邮件经过验证
